Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-Wide Association Study for Glucocorticoid-Induced Ocular Hypertension.

Ophthalmology science·2026
Same author

Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation.

Genes·2026
Same author

Reduction in Pigment Epithelial Detachment Thickness with Faricimab versus Aflibercept 2 mg during Head-to-Head Dosing in TENAYA/LUCERNE.

Ophthalmology science·2026
Same author

Genome-Wide Association Study for Glucocorticoid-Induced Ocular Hypertension.

medRxiv : the preprint server for health sciences·2026
Same author

Gene therapy for AMD: better as an adjuvant than a replacement - Authors' reply.

Lancet (London, England)·2025
Same author

Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema.

Translational vision science & technology·2024

Related Experiment Video

Updated: May 6, 2026

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
07:13

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

12.8K

Assessment of novel guarded needle to increase patient comfort and decrease injection time during intravitreal

Alexander M Eaton, Gabriel M Gordon, Hussein Wafapoor

    Ophthalmic Surgery, Lasers & Imaging Retina
    |November 14, 2013
    PubMed
    Summary

    A new 33-gauge injection device significantly speeds up intravitreal injections. While pain levels were similar, the faster procedure offers potential advantages for patients undergoing this eye treatment.

    More Related Videos

    Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse
    06:46

    Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse

    Published on: July 25, 2025

    1.5K
    Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
    06:19

    Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

    Published on: May 31, 2024

    1.9K

    Related Experiment Videos

    Last Updated: May 6, 2026

    An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
    07:13

    An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

    Published on: December 7, 2016

    12.8K
    Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse
    06:46

    Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse

    Published on: July 25, 2025

    1.5K
    Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
    06:19

    Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

    Published on: May 31, 2024

    1.9K

    Area of Science:

    • Ophthalmology
    • Medical Devices
    • Surgical Innovation

    Background:

    • Intravitreal injections are a common procedure for various eye conditions.
    • Patient comfort and procedure efficiency are key considerations.

    Purpose of the Study:

    • To evaluate a novel guarded 33-gauge injection device for intravitreal injections.
    • To compare its speed and patient comfort against a standard 30-gauge needle.

    Main Methods:

    • A single-center, prospective, randomized interventional study was conducted.
    • Seventy participants received bilateral intravitreal injections, one with the 33-gauge device and the other with a 30-gauge needle.
    • Procedure time and patient-reported pain/comfort were assessed.

    Main Results:

    • Intravitreal injections with the 33-gauge device were significantly faster than with the 30-gauge needle.
    • No significant difference in pain incidence or levels was observed between the two devices.

    Conclusions:

    • The guarded 33-gauge injection device demonstrates potential advantages in reducing procedure time for intravitreal injections.
    • Further research may confirm its benefits for patient management in ophthalmology.